Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections

BACKGROUND: Evaluate the safety and efficacy of 104-week regimen of Telbivudine(LdT)-based optimization strategy for Chinese patients who have chronic hepatits B(CHB) with HBeAg-negative. METHODS: This multi-center, open-label, prospective study enrolled 108 HBeAg-negative CHB patients who received...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Weiqiang, Li, Jianguo, Zhang, Chunlan, Chen, Xuefu, Lin, Chaoshuang, Gao, Zhiliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720458/
https://www.ncbi.nlm.nih.gov/pubmed/33287722
http://dx.doi.org/10.1186/s12879-020-05642-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720458/
https://www.ncbi.nlm.nih.gov/pubmed/33287722
http://dx.doi.org/10.1186/s12879-020-05642-y

Ejemplares similares